Why the study?
ATTR is challenging to diagnose due to diverse presentations and ethnicity-specific mutations, highlighting the importance of early recognition and awareness to facilitate timely diagnosis and treatment.
Highlights a rare Gly67Ala TTR mutation causing cardiac amyloidosis in an Asian female, emphasizing the importance of early screening and genetic testing.
Answers are grounded in this paper and cite their sources.
Rare TTR variant case in Asian female cardiac amyloidosis; hypothesis-generating for ethnicity-specific screening, without practice change.
BACKGROUND: Transthyretin cardiac amyloidosis (ATTR) is a life-threatening, debilitating disease caused by abnormal formation and deposit of transthyretin (TTR) protein in multiple tissues, including myocardial extracellular matrix. It can be challenging to diagnose due to the myriad of presenting signs and symptoms. Additionally, numerous TTR mutations exist in certain ethnicities. Interestingly, our patient was discovered to have a very rare Gly67Ala TTR mutation typically not found in individuals of Asian descent. Recent advances in cardiovascular imaging techniques have allowed for earlier recognition and, therefore, management of this disease. Although incurable, there are now new, emerging treatments that are available for symptom control of cardiac amyloidosis, making early diagnosis vital for these patients, specifically their quality of life. CASE SUMMARY: We outline a case of a 50-year-old Asian female who was initially hospitalized for nausea and vomiting and persistent orthostatic hypotension. She underwent a multitude of laboratory and imaging tests, resulting in a diagnosis of cardiac amyloidosis, which was confirmed to be due to a rare TTR mutation via genetic testing. CONCLUSIONS: Our objective is to describe various TTR mutations, existing diagnostic imaging modalities, and available treatments, as well as highlight the importance of early screening and awareness of cardiac amyloidosis, allowing for quicker diagnosis and treatment of this disease.
No takes yet. Share an insight, caveat, or question.
Mouksian et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: